Celgene Will Provide Fourth Quarter and Full-Year 2007 Guidance at the 26th Annual JP Morgan Healthcare Conference.Company will provide full-year 2008 guidance SUMMIT, N.J. -- Celgene Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CELG) today announced Chief Executive Officer Sol J. Barer, Ph.D., will present fourth quarter and full-year 2007 and 2008 guidance during a presentation at the JP Morgan Healthcare Conference on Monday, January 7, 2008 at 11:30 am EST EST electroshock therapy. EST abbr. electroshock therapy . The event will be webcast live and will be available in the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases Noun 1. inflammatory disease - a disease characterized by inflammation disease - an impairment of health or a condition of abnormal functioning NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants; through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. This release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. which are subject to known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory authorities, and other factors described in the Company's filings with the Securities and Exchange Commission such as our 10K, 10Q and 8K reports. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion